Type 1 Diabetes Research Update - Dr. Charles Dinarello on AAT Research at OmniBio Pharmaceutical
Description: Chief Scientific Officer (CSO) for OmniBio Dr. Charles Dinarello discusses Alpha-1 Antitrypsin (AAT) research and it's potential as a therapy for Type 1 diabetes. He is also a Professor of Medicine and Immunology at the University of Colorado Denver who has published over 700 original research articles on cytokines, particularly interleukin‐1 (IL‐1) and tumor necrosis factor, and is considered a "founding father" of cytokine biology. OmniBio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical‐stage bio pharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug -- Alpha‐1 Antitrypsin (AAT). OmniBio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market. Connect with OmniBio: News: http://OmniBioPharma.com Facebook: http://goo.gl/ue8ou LinkedIn: http://goo.gl/te3ly Visit http://OmniBioPharma.com/investor-relations for SEC filings and additional information. Please refer to Safe Harbor statement at the end of the video. OmniBio, part of the WestMountain Asset Management portfolio, is evaluating AAT for the treatment of several diseases, including Type 1 diabetes, bone marrow transplantation complications (also known as graft versus host disease or GVHD), islet transplantation, HIV, influenza and certain bacterial disorders, including anthrax exposure.. Connect with WestMountain Asset Management: Facebook: http://WestMountainAM.com/FB Twitter: http://WestMountainAM.com/TW LinkedIn: http://WestMountainAM.com/LI Blog: http://WestMountainAM.com/blog
Related tags: graft host disease bone marrow transplant clinical trials alpha type 1 mellitus research cure alpha-1 antitrypsin aat jdrf juvenile children's diabetes foundation pharmaceutical industry stock investment opportunity angel investor equity development public company business finance funding portfolio venture capital startup small cap market financing healthcare health care medical WestMountain West Mountain Asset Management Omni Bio James Crapo Charles Dinarello University of Colorado
Embed: